Literature DB >> 17346310

Anaplasma phagocytophilum specifically induces tyrosine phosphorylation of ROCK1 during infection.

Venetta Thomas1, Erol Fikrig.   

Abstract

Anaplasma phagocytophilum, an obligate intracellular pathogen that persists within polymorphonuclear leucocytes, is the second most common tick-borne agent in North America. We now show that infection of a promyelocytic cell line and neutrophils with A. phagocytophilum results in pathogen-specific tyrosine phosphorylation of ROCK1. Phosphorylation is associated with PSGL-1 and Syk, because PSGL-1 blocking antibodies and siRNA targeting Syk interfere with ROCK1 phosphorylation in A. phagocytophilum-infected cells. Knockdown of either Syk or ROCK1 also markedly impaired A. phagocytophilum infection. These data demonstrate a role for A. phagocytophilum-mediated ROCK1 phosphorylation in infection, and suggests that inhibiting this pathway may lead to new, non-antibiotic strategies to treat human granulocytic anaplasmosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346310     DOI: 10.1111/j.1462-5822.2007.00908.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  26 in total

Review 1.  Mechanisms of obligatory intracellular infection with Anaplasma phagocytophilum.

Authors:  Yasuko Rikihisa
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

2.  Rickettsial pathogen uses arthropod tryptophan pathway metabolites to evade reactive oxygen species in tick cells.

Authors:  Mustapha Dahmani; John F Anderson; Hameeda Sultana; Girish Neelakanta
Journal:  Cell Microbiol       Date:  2020-07-27       Impact factor: 3.715

3.  Neutrophils exposed to A. phagocytophilum under shear stress fail to fully activate, polarize, and transmigrate across inflamed endothelium.

Authors:  U Y Schaff; K A Trott; S Chase; K Tam; J L Johns; J A Carlyon; D C Genetos; N J Walker; S I Simon; D L Borjesson
Journal:  Am J Physiol Cell Physiol       Date:  2010-04-14       Impact factor: 4.249

Review 4.  Anaplasma phagocytophilum: deceptively simple or simply deceptive?

Authors:  Maiara S Severo; Kimberly D Stephens; Michail Kotsyfakis; Joao Hf Pedra
Journal:  Future Microbiol       Date:  2012-06       Impact factor: 3.165

5.  Integrated Metabolomics, Transcriptomics and Proteomics Identifies Metabolic Pathways Affected by Anaplasma phagocytophilum Infection in Tick Cells.

Authors:  Margarita Villar; Nieves Ayllón; Pilar Alberdi; Andrés Moreno; María Moreno; Raquel Tobes; Lourdes Mateos-Hernández; Sabine Weisheit; Lesley Bell-Sakyi; José de la Fuente
Journal:  Mol Cell Proteomics       Date:  2015-09-30       Impact factor: 5.911

6.  c-Jun NH2-terminal kinase 2 inhibits gamma interferon production during Anaplasma phagocytophilum infection.

Authors:  Joao H F Pedra; Jochen Mattner; Jian Tao; Steven M Kerfoot; Roger J Davis; Richard A Flavell; Philip W Askenase; Zhinan Yin; Erol Fikrig
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

Review 7.  Molecular events involved in cellular invasion by Ehrlichia chaffeensis and Anaplasma phagocytophilum.

Authors:  Yasuko Rikihisa
Journal:  Vet Parasitol       Date:  2009-09-19       Impact factor: 2.738

8.  Anaplasma phagocytophilum induces actin phosphorylation to selectively regulate gene transcription in Ixodes scapularis ticks.

Authors:  Hameeda Sultana; Girish Neelakanta; Fred S Kantor; Stephen E Malawista; Durland Fish; Ruth R Montgomery; Erol Fikrig
Journal:  J Exp Med       Date:  2010-07-26       Impact factor: 14.307

9.  Anaplasma phagocytophilum increases cathepsin L activity, thereby globally influencing neutrophil function.

Authors:  Venetta Thomas; Swapna Samanta; Erol Fikrig
Journal:  Infect Immun       Date:  2008-09-02       Impact factor: 3.441

10.  Sialyl-Lewis x-independent infection of human myeloid cells by Anaplasma phagocytophilum strains HZ and HGE1.

Authors:  Madhubanti Sarkar; Dexter V Reneer; Jason A Carlyon
Journal:  Infect Immun       Date:  2007-09-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.